Categorynews

Small-Cell Lung Cancer (SCLC) Market Spotlight Report 2019 – ResearchAndMarkets.com

June 18, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Small-Cell Lung Cancer (SCLC)” report has been added
to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the small cell lung cancer market,
comprising key pipeline and marketed drugs, recent events and analyst
opinion, probability of success, clinical trials, upcoming and
regulatory events, patent information, a 10-year disease incidence
forecast, licensing and acquisition deals, and drug-specific revenue
forecasts

Key Takeaways

  • The report estimates that in 2017, there were 310,300 incident cases
    of small cell lung cancer (SCLC) worldwide, and forecasts that number
    to increase to 339,500 incident cases by 2026.
  • Northern America is estimated to have the highest disease incidence
    (10.43 per 100,000 people), while Africa has the lowest incidence
    (0.47 per 100,000 people).
  • Celgene’s Amrubicin, Novartis’s Hycamtin (topotecan), Aeterna’s
    Lobaplatin, and Bristol-Myers Squibb’s Opdivo (nivolumab) are the only
    marketed drugs for SCLC. These drugs are administered via the oral or
    intravenous routes.
  • The majority of industry-sponsored drugs in active clinical
    development for SCLC are in Phase II, with only one drug in the
    NDA/BLA phase.
  • Therapies in mid-to-late-stage development for SCLC focus on a wide
    variety of targets. The majority of the drugs in mid-to-late stage
    development are administered via the intravenous route, with the
    remainder being oral, intratumoral, intramuscular, or subcutaneous
    formulations.
  • High-impact upcoming events for drugs in the SCLC space comprise
    topline Phase I/II, Phase II/III, and Phase III trial results, and an
    FDA decision on an sBLA.
  • The overall likelihood of approval of a Phase I solid tumor asset is
    5.7%, and the average probability a drug advances from Phase III is
    39.4%. Drugs, on average, take 9.5 years from Phase I to approval,
    compared to 9.2 years in the overall oncology space.
  • There have been 10 licensing and asset acquisition activities
    involving SCLC drugs during 2014-19. The license agreement made in
    2017 between CytRx and NantCell for the exclusive rights to develop
    and market aldoxorubicin for $356m was the largest deal during the
    period.
  • The distribution of clinical trials across Phase I-IV indicates that
    the vast majority of trials for SCLC have been in the early and
    mid-phases of development, with 89% of trials in Phase I-II, and only
    11% in Phase III-IV.
  • The US has a substantial lead in the number of SCLC clinical trials
    globally. The UK leads the major EU markets, while Japan has the top
    spot in Asia.
  • Clinical trial activity in the SCLC space is dominated by completed
    trials. GlaxoSmithKline and Pfizer have the highest number of
    completed clinical trials for SCLC, with 43 and 41 trials,
    respectively.
  • Pfizer leads the industry sponsors with the highest number of clinical
    trials for SCLC, followed by GlaxoSmithKline.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Chemotherapy

Radiotherapy

Surgery

Palliative procedures

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Rova-T for SCLC (December 5, 2018)

Opdivo for SCLC (November 26, 2018)

Trilaciclib for SCLC (November 26, 2018)

Trilaciclib for SCLC (October 21, 2018)

Opdivo for SCLC (October 12, 2018)

Tecentriq for SCLC (September 25, 2018)

Opdivo for SCLC (August 16, 2018)

Tecentriq for SCLC (June 25, 2018)

Rova-T for SCLC (March 22, 2018)

Trilaciclib for SCLC (March 5, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Tecentriq’s SCLC Success Takes Edge Off Roche’s IO Position

Bristol’s Opdivo Enjoys IO First-Mover Advantage In SCLC

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/is9n3z

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Lung
Cancer Drugs